VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
Menée notamment à l'aide d'un modèle murin de cancer de la prostate et à partir de tissus tumoraux, cette étude met en évidence, chez les patients atteints d'un cancer de la prostate traité par ipilimumab, une augmentation de l'expression de VISTA, une protéine impliquée dans le contrôle de la réponse immunitaire
To date, anti-CTLA-4 (ipilimumab) or anti-PD-1 (nivolumab) monotherapy has not been demonstrated to be of substantial clinical benefit in patients with prostate cancer. To identify additional immune-inhibitory pathways in the prostate-tumor microenvironment, we evaluated untreated and ipilimumab-treated tumors from patients in a presurgical clinical trial. Levels of the PD-L1 and VISTA inhibitory molecules increased on independent subsets of macrophages in treated tumors. Our data suggest that VISTA represents another compensatory inhibitory pathway in prostate tumors after ipilimumab therapy.